NASDAQ · Biotechnology

Atara Biotherapeutics, Inc. (ATRA) Stock

$7.71 -2.41% NASDAQ: ATRA Healthcare

Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies.

Valuation

MetricValue
Price$7.71
Market Cap$69.47M
P/E Ratio-11.97
P/B Ratio-2.98
P/S Ratio3.08
EPS (TTM)$0.00
52-Week High$19.14
52-Week Low$3.92
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE25.68%
ROA-47.34%
ROCE-43.96%
Gross Margin29.75%
Operating Margin29.75%
Net Margin-40.91%
Debt/Equity-0.27
Current Ratio0.80

Annual Financials (USD)

Metric20212022202320242025
Revenue$20.0M$64.0M$9.0M$129.0M$121.0M
Operating Profit$-340.0M$-281.0M$-276.0M$-83.0M$36.0M
Net Profit$-340.0M$-228.0M$-276.0M$-85.0M$33.0M
EPS$-90.78$-55.96$-65.18$-11.41$2.57
Op Margin-1673.8%-441.3%-3219.5%-64.7%29.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$468.0M$376.0M$166.0M$109.0M$20.0M
Total Liabilities$189.0M$250.0M$265.0M$206.0M$59.0M
Cash$106.0M$93.0M$26.0M$25.0M$8.0M
Borrowings$28.0M$72.0M$58.0M$44.0M$53.0M

Latest News

Biotech Stocks Surge As UniQure 'Nail-Biting Journey' Comes To An End Investor's Business Daily · Jun 17, 2026 Atara Biotherapeutics Announces Changes to Its Board of Directors Business Wire · Jun 12, 2026 ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know Zacks · May 21, 2026 Atara Biotherapeutics: Q1 Earnings Snapshot Associated Press · May 12, 2026 FDA Resubmission Path for Tab-cel Keeps Atara’s (ATRA) Regulatory Timeline Alive InvestorsHub · May 7, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-221.0M$-270.0M$-193.0M$-69.0M$-51.0M
Investing Cash Flow$12.0M$199.0M$123.0M$8.0M$18.0M
Financing Cash Flow$6.0M$32.0M$1.0M$0$0
Net Cash Flow$-94.0M$-14.0M$-67.0M$-1.0M$-17.0M
Free Cash Flow$-231.0M$-275.0M$-194.0M$-69.0M$-51.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.09
EV / EBITDA3.01
FCF Yield-73.41%
Quick Ratio0.80
Interest Coverage9.00
Return 1Y-7.87%
Return 3Y-81.33%
Return 5Y-97.42%

Ownership

Insiders Held16.92%
Institutions Held52.46%
Institutions Float Held63.15%
Institutional HolderSharesReport Date
Adage Capital Partners GP L.L.C.700,0002026-03-31
Redmile Group, LLC441,7012026-03-31
Mackenzie Financial Corporation313,6202026-03-31
Vanguard Capital Management LLC217,8622026-03-31
Point72 Asset Management, L.P.194,2642026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CLNNClene Inc. $5.29 -1.86% -1.66 $54.53M 0.00%
CNTX $0.62 +4.47% -6.84 $56.69M 0.00%
COYA $4.00 -6.21% -2.62 $72.84M 0.00%
CSBR $5.19 +0.00% 18.33 $72.11M 0.00%
IFRX $1.84 +6.98% -4.16 $132.91M 0.00%

About Atara Biotherapeutics, Inc.

Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments for patients battling cancer, autoimmune disorders, and viral infections. A key therapeutic candidate, tabelecleucel, is currently undergoing Phase 3 clinical trials for Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease, as well as various hematologic and solid tumors, such as nasopharyngeal carcinoma. The company is also advancing a robust pipeline of next-generation CAR T immunotherapies designed to combat hematologic malignancies and solid tumors. This includes ATA2271 and ATA3271 targeting mesothelin, alongside ATA2431 and ATA3219 for B-cell malignancies. Furthermore, Atara is developing ATA188 for the treatment of multiple sclerosis and the ATA368 program specifically for cancers associated with human papillomavirus (HPV). To bolster its research and development efforts, Atara Biotherapeutics has established significant collaborations and licensing agreements. These include a licensing partnership with Memorial Sloan Kettering Cancer Center, a license and R&D collaboration with QIMR Berghofer Medical Research Institute, and a strategic alliance with H. Lee Moffitt Cancer Center. Additionally, the company holds a strategic partnership with Bayer AG focused on mesothelin-targeted CAR T-cell therapies for solid tumors.

Atara Biotherapeutics, Inc. is led by CEO Anhco Nguyen, employs 153 people, headquartered in US, publicly traded since 2014.

Atara Biotherapeutics, Inc. (ATRA) stock trades at $7.71 with a market capitalization of $69.47M. The stock is valued at a price-to-earnings (P/E) ratio of -11.97, price-to-book of -2.98, price-to-sales of 3.08. Over the past 52 weeks the stock has ranged between $3.92 and $19.14, and currently trades 59.7% below its 52-week high.

On profitability, Atara Biotherapeutics, Inc. generates a return on equity (ROE) of 25.68% — well above the market average, a sign of a high-quality business, return on capital employed of -43.96%, an operating margin of 29.75%, a net profit margin of -40.91%.

Official website: www.atarabio.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides